Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Real-world study determining the safety and efficacy of teclistamab in R/R multiple myeloma

Shonali Midha • 29 Sep 2023
IMS 2023
Multiple Myeloma Antibodies Teclistamab
MajesTEC-1

Shonali Midha, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a real-world study determining the safety and efficacy of teclistamab, a BCMA-targeting bispecific antibody, in the treatment of patients with relapsed/refractory (R/R) multiple myeloma. Dr Midha compares the findings of this real-world study with results from the MajesTEC-1 trial (NCT04557098). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Pfizer, AbbVie

More from Shonali Midha

1:12
Determinants of response and resistance to T-cell engaging therapies in multiple myeloma
Shonali Midha • 29 Sep 2023
1:24
Disparities in access and practice patterns of BCMA-directed therapies in multiple myeloma
Shonali Midha • 29 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals